Neracorvir

Neracorvir is an investigational new drug that is being evaluated by Fujian Cosunter Pharmaceutical Company, Ltd. for the treatment of chronic hepatitis B virus (HBV) infections.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Neracorvir is an investigational new drug that is being evaluated by Fujian Cosunter Pharmaceutical Company, Ltd. for the treatment of chronic hepatitis B virus (HBV) infections. It binds to the hepatitis B core (capsid) protein interfering with hepatitis B capsid assembly and viral replication. Neracorvir is sometimes referred to as a HBV core protein modulator, but in HBV, the core and capsid proteins are one in the same.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1367208886 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.